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Abstract
Introduction: Drug-induced hepatitis is common in clinical practice. This problem is particularly relevant in the treat-
ment of tuberculous infection, because for this purpose, up to 5–6 hepatotoxic drugs are used simultaneously for a long 
time, which often (in 15–20% of cases) leads to medical liver lesion. To protect the liver, Semax and Selank are offered 
– drugs of regulatory peptides group.
Materials and Methods: The research was conducted on 96 outbred white male rats weighing 180–220 g. The experi-
mental group included about 10 animals. Drug-induced hepatitis was simulated through the combined 21-day adminis-
tration of isoniazid, rifampicin and ethanol. Semax and Selank, as well as Essentiale N and Mexidol (comparison drugs) 
were administered once a day during the experiment. Healthy control animals with experimental hepatitis were used for 
comparison. Subsequently, the obtained biochemical and histomorphological parameters were evaluated.
Results and Discussion: In the experiment, Semax and Selank showed a greater therapeutic activity than the rec-
ognized hepatoprotectors – Essentiale and Mexidol. Only in the case of administering Selank and Semax, there was 
parallelism between the restoration of biochemical parameters of blood and histomorphological parameters of the liver. 
Selank was also characterized by an increased activity of regenerative processes.
Conclusion: Administering Selank and Semax to patients with tuberculosis would significantly reduce the number and 
severity of hepatotoxic reactions.
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Introduction
The recent decades have seen a growth in liver diseases 
due to a hectic pace of life lined with stress and overwork, 
industrialization and environment pollution, professional 
and household hazards, an increased consumption of 
abused drugs and alcohol, imbalanced diets, an increase 
in the number of tuberculosis patients and uncontrolled 
medication intake (Kovtun et al. 2011, Poluchova et al. 
2018, Topchiy and Toporkov 2013). Among the most wi-
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despread liver infections are acute and chronic viral hepa-
titis (for example, nearly 170 million people in the world 
have chronic hepatitis C), and among non-infectious ones 
– non-alcoholic fatty liver disease (Kolesnikova and Niki-
forova 2014, Lazo et al. 2013, Vernon et al. 2011, Williams 
et al. 2011). Alcoholic liver disease is of great concern in 
the the Russian Federation, for 14–20 thousand people die 
from it annually (Homeriki and Homeriki 2012).
In recent years, drug-induced and toxic hepatitis have 
occured more and more often (up to 30% of all acute he-
patitis) (Bandegi et al. 2014, Shapiro and Lewis 2007). 
Drug-induced liver disease may develop due to drug 
properties, patients’ body features, their liver condition, 
a diet and other factors. According to the world statistics, 
drug-induced liver lesion (DILL) make up from 0.7% to 
20% of cases, with every seventh patient with this pa-
thology dying (Chalasani et al. 2008, Kovtun et al. 2011, 
Topchiy and Toporkov 2013). Drug hepatotoxicity is the 
main reason in the development of liver failure requiring 
liver transplantation (Kovtun et al. 2011).
The main groups of drugs causing DILL appeared to 
be anti-infections drugs influencing the central nervous 
system, locomotor system (for example, nonsteroidal an-
ti-inflammatory drugs) and gastrointestinal tract (Chala-
sani et al. 2008). The liver lesion is described for more 
than 1,000 drugs (Bandegi et al. 2014).
Drug-induced lesion of liver caused by the use of an-
tibacterial remedies are characterized with considerable 
variability in both frequency and type of liver lesion. Very 
often hepatitis occurs as a complication after administe-
ring anti-tuberculosis drugs (for example, up to 2,000 per 
100,000 prescriptions of isoniazid) (Ivanova and Borisov 
2017, Zuckerman 2011).
A considerable increase in the number of rapidly pro-
gressing and widespread forms of tuberculosis. as well as 
the growth of polyresistant forms of mycobacteria of tu-
berculosis (MBT) make it imperative that a combination 
of 5–6 drugs is used in chemotherapy, which provokes the 
development of toxic hepatitis (Federal Clinical Recom-
mendations 2014).
It is known that major anti-tuberculosis drugs (iso-
niazid, ethambutol, ethionamide, pyrazinamide and ri-
fampicin) have hepatotoxical properties and provoke the 
development of toxic hepatitis, and their combined ad-
ministration intensifies the toxic effect. The frequency of 
DILL during polychemotherapy of tuberculosis is 15%-
20%, which creates risks for administering a complete 
course of chemotherapy. Irregular administration of an-
ti-tuberculous drugs reduces treatment efficacy and leads 
to forms of tuberculosis with wide drug resistance, as well 
as to an increase in the reservoir of tuberculous infection 
(Drobin 2014, Ivanova and Borisov 2017, Mordyk et al. 
2014, Testov et al. 2014).
In tuberculous therapy, isoniazid is most often used, 
which after acetylation becomes hydrazine, from which a 
potent combination is formed in the liver, leading to de-
struction of hepatocytes. The toxic action of isoniazid is 
increased if administering it along with inducers of cy-
tochrome enzyme system, for example with rifampicin, as 
well as with alcohol, anaesthetics and paracetamol (Cai et 
al. 2012, Kazakov et al. 2018).
The treatment of DILL requires abolishing all other 
drugs, except for the life-saving ones. For pathogenic 
therapy, hepatoprotectors are used, selected in accordan-
ce with the main mechanism of the disease development 
(Minushkin et al. 2016). The effect of hepatoprotectors is 
aimed at restoration of homeostasis in the liver, increasing 
its resistance to pathogenic factors, normalization of func-
tional activity and stimulation of reparative-regenerative 
processes in the liver (Kovtun et al. 2011, Kucheryavyy 
and Morozov 2012, Vyalov 2013). The biochemical me-
chanism of protective action of most hepatoprotectors 
includes membrane stabilizing (increased activity and 
membrane fluidity, decreased density in the mosaic ma-
trix of phospholipid element membranes and normaliza-
tion of their penetration, activation of phospholipid-de-
pendant ferments), anti-oxydative (inhibition of lipid 
peroxidation, a decreased rate of free radical synthesis), 
anti-phibrotic, regenerative (an increasing in ribonucleic 
acid and albumin synthesis by hepatocytes) and hypolipi-
demic effects (Yakovenko et al. 2017).
Practically all liver toxins stimulate several pathogenic 
ways, leading, as a rule, to necrotic death of liver cells 
(mediator-hormonal imbalance, activation of POL, oxida-
tion stress, damage to phospholipids of cellular and mi-
tochondrial membranes, etc.). At the same time, hepato-
protectors have their own role in the pathological process, 
without overlapping all the pathogenesis links of drug-in-
duced hepatotoxicity, which requires combining several 
drugs with each other or using their maximum dosage. 
Unfortunately, such an approach to prescribing hepato-
protectors leads not only to an increase in the therapy effi-
cacy, but also to a considerable increase in the number of 
side effects (Vyalov 2013).
What is more, the hepatoprotective therapy itself has 
some negative aspects: adverse side effects, drug inter-
action, and the variability of clinical effects of drugs by 
different producers, a rather narrow spectrum of therapeu-
tic efficacy, which makes it necessary to combine drugs 
of different groups (Babayan and Havkin 2013, Crocenzi 
and Roma 2006, Matveev et al. 2011).
Another negative aspect is as follows: drugs containing 
the same substance may be produced in different coun-
tries, and clinical experience shows that the therapeutic 
actions they have are far from being similar. Phytogenic 
drugs may act differently depending on places where the 
herbs used for their production grew (Matveev et al. 2011, 
Minushkin et al. 2016).
One of the ways to solve this problem is to introduce 
into medical practice the drugs that, on t home hand, have 
versatile physiological effects, and, on the other hand, 
provide a high degree of safety. Such hepatoprotective 
drugs as glyprolines, possessing properties of regulatory 
peptides (RP), meet these requirements. In case of va-
rious diseases, RPs activate the self-regulation processes 
and self-repair of disrupted functions of affected organs 
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and systems. An important aspect of using regulatory oli-
gopeptides is their capacity to normalize the level of tis-
sue trophic factors which, on the one hand, inhibit various 
mechanisms of a pathological cascade, but, on the other 
hand, stimulate reparative processes (Myasoedov 2016).
The typical representatives of the RP class are Se-
max and Selank, belonging to the glyproline family 
(Myasoedov 2016). Semax is a synthetic peptide based 
on fragments of adrenocorticotropic hormone (ACTH) 
4–7 (Met-Glu-His-Phe), whereas the structure of Selank 
is based on peripheral immunomodulator taftsin (H-Thr-
Lys-Pro-Arg-OH). To protect from the hydrolysed acti-
on of peptidases, tripeptide Pro-Gly-Pro, which has a 
cytoprotective activity, was added to them in C-position 
(Myasoedov 2016). The introduction of Semax and Se-
lank to the body promotes activation of the peptidergic 
system and secondary synthesis of a wide range of regula-
tory peptides (Solovyev et al. 2011). They prevent the li-
ver damage in stress situations (Ivanov et al. 2017). They 
contribute to regulation of inflammatory processes due to 
reducing the level of cytokine imbalance and normalizing 
the activity of the kinin and bradikinin system, and also 
reduce the activity of apoptosis in the damaged tissues. 
The drugs are characterised with a high level of safety 
(Myasoedov 2016).
The purpose of this research is to study a hepatoprotec-
tive effect Selank and Semax in liver damage caused by 
anti-tuberculous drugs.
Materials and methods
The research was conducted on 96 outbred white male rats, 
each weighing 180–220 g. The experimental group inclu-
ded at least 10 animals. The laboratory animals were trea-
ted according to the Rules of Laboratory Practice (On the 
Approval of Rules of Laboratory Practice, Order no. 708n 
of the Ministry of Healthcare and Social Development of 
the Russian Federation of August 23, 2010). All the ani-
mals were kept in the identical standard conditions of care.
Drug-induced hepatitis was simulated through a com-
bined administration of isoniazid (100 mg/kg, intragastri-
cally), rifampicin (130 mg/kg, intragastrically) and a 25% 
ethanol solution (3gr/kg, intragastrically) for 21-days. A 
number of biochemical parameters were studied in the 
blood of the animals on the 22nd day after the start of ad-
ministering liver toxicants. These biochemical parameters 
were combined into functional groups: cytolysis markers 
(activity of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma-glutamyltransferase 
(GGT), lactate dehydrogenase (LDG)); indicators of pro-
tein-synthetic activity of hepatocytes (total protein, albu-
mins, globulins), carbohydrate metabolism (the activity of 
total and pancreatic alpha-amylase, the content of gluco-
se), lipid metabolism (the activity of lipase, the content of 
triglycerides (TG), total cholesterol (Ch.T), cholesterol of 
high-density lipoproteins (HDL) and low-density lipopro-
teins (LDL)), and detoxification function of liver (contents 
of direct bilirubin). The osmotic resistance of erythrocytes 
(ORE) was studied with a standardized method.
During histomorphological research, the general evalu-
ation of preparations was carried out by hematoxilin and 
eosin staining; collagen fibers were shown by Masson stai-
ning; elastic fibers were stained by fukselin (with Hart’s 
staining), and reticuline fibers – by Foot’s silver impregna-
tion. A stereometrical study of liver was done to define the 
correlation between different tissue compounds.
Semax and Selank were administered intranasally 0.04 
ml in each nasal passage; the dosage was 0.2 mg/kg. For 
comparison, hepatoprotectors were used, such as Essenti-
ale N and Mexidol (administered hypodermically at 1 ml/
kg and 50 mg/kg, respectively). All the drugs were admi-
nistered once a day during the whole experiment. Compa-
rison was made between the healthy control groups and 
the animals with simulated hepatitis (the rats were admi-
nistered saline solution).
All the calculations were done using Biostatistics soft-
ware (StatPlus Professional 5.8). The number of measur-
ments of each parameter in different experiments was 10–
18. For intergroup comparison, there was used Student’s 
t-criterion (in case of normal distribution) and a non-para-
metric Wilcoxon criterion (with no normal distribution); 
for multiple comparisons, Student criterion with a Bon-
ferroni’s adjustment was used. The significance of intra-
group differences was defined by paired Student’s t-crite-
rion. The difference was considered significant at p<0.05.
Results and discussion
The analysis of dynamic activities of cytolytic enzymes 
in blood showed (Table 1) that in the case of toxic he-
patitis there was a statistical increase in AST and ALT 
by 46% and 21%, respectively, and a tendency towards 
a 15% increase in total LDH activity, but, at the same 
time, the activity of GGT remained unchanged. All this 
points at moderate hepatocytes cytolysis. Administration 
of Essentiale and Mexidol for hepatitis treatment did not 
prevent the destruction of hepatocytes, but the level of 
cytolysis somewhat decreased: Essentiale prevented an 
increase in the AST activity in blood (though the ALT ac-
tivity remained 35% higher than usual), and Mexidol pre-
vented an increase in ALT (with AST increasied by 36%, 
Table 1. The Influence of Tested Drugs on Hepatocytes Cytol-
ysis Activity.
Groups ALT un/L AST un/L GGT un/L LDG un/L
intact 103.3±11.5 136.5±6.7 5.46±0.76 628±58
control 150.6±14.5* 164.5±11.1* 5.98±0.74 722±74
hepatitis + Semax 102.2±21.1 114.5±9.8** 5.78±0.46 356±41*/**
hepatitis + Selank 132.7±15.6 149.7±6.5 5.44±0.74 647±81
hepatitis + Essentiale 139.3±10.1* 138.5±7.7 6.28±0.56 433±20*/**
hepatitis + Mexidol 129.5±11.8 185.2±19.1* 6.72±0.86 472±43**
Note: * – statistical difference with intact animals (p<0.005); ** – statistical dif-
ference with control animals (p<0.05); ALT – activity of alanine aminotransferase, 
AST – aspartate aminotransferase, GGT – gamma-glutamyltransferase, LDG – 
lactate dehydrogenase.
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p<0.05). On the contrary, Selank and Semax prevented 
an increase in the activity of blood transaminases: as for 
AST, Semax decreased its activity statistically by 30% as 
compared to that in the control group.
Protein metabolism imbalance is a typical effect for 
liver damage. The 21-day administration of hepatotoxic 
drugs (Table 2) to the control rats caused a statistical de-
crease in the total protein level in blood by 16% due to a 
drop in albumin concentration (-23%, p<0.05); no statis-
tical changes in the globulin concentration in blood were 
registered. Administering Selank and Essentiale normali-
zed all disrupted indices. Semax had almost no influence 
on the total protein content in blood, but somewhat in-
creased the albumin level (by 15%, p>0.05) as well as 
statistically decreased the globulin concentration in blood 
by 21% in the intact animals. Mexidol administration was 
not effective.
During hepatitis simulation, there was a statistical re-
duction in amylase activity by 17%, with glucose content 
in blood remaining at the normal level (Table 3). Out of 
the tested drugs, only administration of Selank caused the 
normalisation of amylase activity. Semax, Mexidol and 
Essentiale did not influence the activity of alpha-amylase 
(the recorded decrease was 16–23%), but a decrease in 
the level of glucose in blood by 22% was observed after 
administering Essentiale.
The liver is the key organ in lipid metabolism: chole-
sterol and lipoproteins, its transporters, are synthesized 
in hepatocytes; it is also the place of most synthesis of 
phospholipids and endogenic triglycerides. When simu-
lating toxic hepatitis in rats (Table 4), there was a decre-
ase in blood lipase activity (-57% at p<0.05) against the 
background of a statistical increase in the triglyceride 
concentration (+43%) in blood and a tendency towards an 
increase in the total cholesterol level (+20% at p<0.05).
Administering Semax, Selank and Essentiale prevents 
the disruption of lipid metabolism in simulated hepatitis, 
whereas Mexidol only normalizes the lipase activity, but 
does not prevent a 78% growth in triglyceride concentra-
tion in blood (at p<0.05) and, above all, with its admi-
nistration statistically decreases the level of high-density 
lipoprotein cholesterol by 28%.
One of main functions of the liver is detoxification: the 
organ detoxicates both exogenous and endogenous toxic 
products. The latter include direct bilirubin, the level of 
which increased by 27% (Table 5) in the sick rats. The 
use of Essentiale was not effective, and the administrati-
on of Mexidol decreased detoxification properties of the 
liver: concentration of direct bilirubin in blood statisti-
cally increased by 41% compared to control and by 79% 
as compared to the intact animals. The administration of 
Semax and Selank restored the detoxification function of 
hepatocytes. Semax was the most active, as it statistical-
ly decreased the level of direct bilirubin in blood by 1.5 
times as compared to the control group.
The osmotic resistance of erythrocytes (ORE) is an 
integral indicator of the body’s resistance to lipid peroxi-
dation; there is also a close connection between changes 
in the permeability of erythrocyte membranes and of the 
membranes of cells affected by a pathological process 
(Zakharova et al. 1991).
When simulating toxic hepatitis, there was a statisti-
cal decrease in ORE by 30% in the animals. Gliprolines 
and Mexidol prevented an increase in the erythrocytes 
hemolysis level under hypo-osmotic conditions; Essen-
tiale, though it increased the erythrocytes resistance to 
a 0.5% solution of NaCl (by 21% at p<0.05 as compa-
red to the control group), with ORE remaining lower 
(by 15%) than in the intact rats. The obtained results 
made it possible to suppose that the tested drugs, while 
limiting the activity of free-radical oxidation of lipids, 
prevent the impairment of cytoplasmic membrane func-
Table 4. The Influence of Tested Drugs on the Lipid Metabolism in Simulated Hepatitis.
Groups Lipasa un/L Triglyceride mmol/L Total cholesterol mmol/L LDL mmol/L HDL mmol/L
intact 220.0±50.6 0.54±0.03 1.60±0.13 0.87±0.07 0.43±0.05
control 94.8±7.6* 0.77±0.10* 1.93±0.11 0.90±0.07 0.46±0.03
hepatitis + Semax 464.6±120.6** 0.71±0.15 1.70±0.22 0.74±0.17 0.37±0.08
hepatitis + Selank 378.0±106.2** 0.56±0.06** 1.71±0.14 1.09±0.06** 0.40±0.04
hepatitis + Essentiale 261.2±90.4 0.49±0.10 1.63±0.11 0.81±0.06 0.37±0.03**
hepatitis + Mexidol 375.2±141.6 0.96±0.18* 1.66±0.16 0.63±0.08*/** 0.38±0.09
Note: * – statistical difference with intact animals (p<0.05);** – statistical difference with control animals (p<0.05); HDL – high-density lipoproteins; LDL – low-density 
lipoproteins.
Table 2. The Influence of Tested Drugs on Synthesis of Protein 
in Liver Against the Background of Simulated Hepatitis.
Groups Total protein g/L Albumins g/L Globulins g/L
intact 64.3±1.2 33.7±0.6 30.6±0.5
control 54.2±2.7* 26.0±1.1* 28.2±1.2
hepatitis + Semax 53.9±2.5* 29.8±1.0* 24.1±0.8*/**
hepatitis + Selank 59.6±2.1 31.6±1.1** 28.0±1.2
hepatitis + Essentiale 62.6±1.5** 32.3±0.5** 30.3±0.6**
hepatitis + Mexidol 51.4±4.2* 29.0±1.0* 22.4±1.0*/**
Note: * – statistical difference with intact animals (p<0.005); ** – statistical differ-
ence with control animals (p<0.05).
Table 3. The Influence of Tested Drugs on the Carbohydrate 
Metabolism Rate in Case of Simulated Hepatitis.
Groups Аlpha amylase un/L Аlpha-amylase 
pancreatic un/L
Glucose 
mmol/L
intact 2173±94 1218±53 8.6±0.4
control 1796±60* 1012±41* 8.7±0.4
hepatitis + Semax 1776±92* 991±51* 8.5±0.9
hepatitis + Selank 2024±104** 1135±61 8.1±0.3
hepatitis + Essentiale 1656±65* 935±40* 6.7±0.4 */**
hepatitis + Mexidol 1493±67*/** 796±63*/** 8.6±0.6
Note: * – statistical difference with intact animals (p<0.005); ** – statistical differ-
ence with control animals (p<0.05).
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tions, limiting cytolysis and disturbance of metabolic 
processes in the liver.
The simulation of drug-induced hepatitis revealed sig-
nificant histomorphological changes in the liver structu-
re. In the liver, there developed a sharp hyperaemia of 
the arterial and venous networks; there was an expansion 
of sinusoids and lymphatic channels. At the same time, 
extralobular stroma was infiltrated by mononuclear cells, 
neutrophils and eosinophils; besides, a growth of fibrous 
connective tissue was also observed, including that in 
vessels (arteries and branches of the portal vein) and bile 
ducts. Hepatocytes underwent hydropic protein degenera-
tion, sometimes turning into focal necrosis, which caused 
a decrease in the specific area of parenchyma. The spe-
cific area of hepatocytes decreased 1.3 (p<0.001) times 
as compared to the control group. And vice versa, the 
specific area of sinusoids increased 1.3 (p<0.001) times, 
and the specific area of the stroma increased 1.2 (p<0.05) 
times (Table 6). On the whole, the morphological pictu-
re may be characterized as chronic active hepatitis with 
fibrosis of stroma, and hepatitis in the experiment in its 
structural manifestations fully complied with that obser-
ved in clinical practice.
After administering Selank and Semax, a regress of 
pathological changes in the liver tissue was observed: in-
flammatory hyperaemia of inflow and outflow blood ves-
sels of liver, as well as of sinusoids, decreased sharply; 
sclerotic changes in bothe arterial walls and in portal vein 
branches decreased equally well, and their tonus returned 
to normal. Besides, the usual lobular stricture of liver was 
preserved, and there were no signs of liver cell damage, 
such as degeneration and necrosis. A considerable diffe-
rence of Selank from Semax was the reinforcement of re-
generation processes in liver parenchyma, which showed 
in an increase in and hyperchromatosis of cellular nuclei 
and the emergence of dual-core forms, as well as consi-
derably less expressed inflammatory infiltration of portal 
tracts and a noticeable decrease in the sclerosis level and 
the area of the portal stroma.
After administering Essentiale, minor positive dyna-
mics was observed in the rats. The differences mostly 
concerned the liver parenchyma, in which there were no 
signs of serious damage in the form of small foci of ne-
crosis; at the same time dystrophic changes in liver cells 
were expressed as much as in the control group. Inflam-
matory infiltration, sclerotic process in the portal stroma 
and vascular walls of arteries and veins showed no in-
volution. When administering Mexidol, no considerable 
morphological differences were observed.
A stereometrical study showed that (Table 7) all the 
tested drugs prevented a statistical decrease in the speci-
fic area of hepatocytes as compared to the sick animals. 
However, normalization of this indicator is only obser-
ved when administering Selank and Semax, which sta-
tistically increased it as compared to the control group 
by 22 and 20% (p<0.01), respectively. An increase in the 
specific area of sinusoids by 21–31% occurred when ad-
ministering all the tested drugs, but it was observed to a 
lesser extent when using Selank (there was a 9%, decre-
ase; p>0.05). Also, only Selank and Semax prevented an 
increase in the area of the stroma? with Selank stratis-
tically decreasing it by 14% as compared to the control 
group. That is, this can mean the anti-fibrotic activity of 
the drugs in question.
Lethality of the animals is the most important integral 
indicator of the effect of toxic agents on the organism. 
While simulating toxic hepatitis, there was a 20% letha-
lity of animals. Administration of Semax, Selank and 
Essentiale completely prevented it, whereas Mexidol 
was ineffective.
The research showed that when simulating drug-indu-
ced hepatitis in white rats by means of hepatotoxic agents 
(isoniazid, rifampicin and ethanol), a universal link of 
the mechanism of liver tissue damage was activated, that 
is lipid peroxidation, which resulted in the disruption of 
the integrity of liver cell membrane structures, a cytolytic 
syndrome, necrotic death of some hepatocytes and subse-
quent fibrosis. This led to a protein, carbohydrate and lipid 
metaboliс imbalance, as well as to a impaired detoxifica-
tion function of the liver. The disruption of biochemical 
processes was accompanied by obvious morphological 
changes in the liver.
Table 5. Influence of Tested Drugs on the Detoxification Func-
tions of Liver Indices in Simulated Hepatitis.
Groups Direct bilirubin mkmol/L
intact 0.52±0.02
control 0.66±0.05*
hepatitis + Semax 0.44±0.06**
hepatitis + Selank 0.56±0.09
hepatitis + Essentiale 0.70±0.08*
hepatitis + Mexidol 0.93±0.11*/**
Note: * – statistical difference with intact animals (p<0.05); ** – statistical differ-
ence with control animals (p<0.05).
Table 6. Influence of Tested Drugs on Osmotic Resistance of 
Erythrocytes (ORE) in Simulated Hepatitis.
Groups ORE (% of hemolysis)
intact 55.1 ± 3.2
control 78.1 ± 4.6*
hepatitis + Semax 59.2±4.7**
hepatitis + Selank 62.3±4.2**
hepatitis + Essentiale 64.8 ± 3.5*/**
hepatitis + Mexidol 60.7 ± 4.1**
Note: * – statistical difference with intact animals (p<0.05); ** – statistical differ-
ence with control animals (p<0.05).
Table 7. Stereometrical Research of Liver Tissue in Intact and 
Control Group of Rats (%).
Groups Hepatocytes Sinusoids Stroma
intact 58.2±2.3 29.6±1.2 8.5±0.3
control 46.7±2.1* 38.8±2.0* 10.3±0.4*
hepatitis + Semax 55.1±2.4** 37.6±1.8* 9.1±0.5
hepatitis + Selank 56.9±2.2** 35.7±1.7* 8.9±0.3**
hepatitis + Mexidol 52.0±2.2 38.6±2.1* 10.3±0.5*
hepatitis + Essentiale 54.2±2.4 38.2±2.0* 10.0±0.6*
Note: * – statistical difference with intact animals (p<0.05); ** – statistical differ-
ence with control animals (p<0.05).
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In the treatment of drug-induced hepatitis, Semax and, 
especially, Selank showed a greater therapeutic activity than 
the recognized hepatoprotectors – Essentiale and Mexidol. 
All the four drugs promoted the normalization of biochemi-
cal indicators in blood of the sick animals to a greater (with 
Selank and Semax) or smaller (with Essentiale and Mexi-
dol) degree. However, only in the case of administering Se-
lank and Semax, the restoration of biochemical indicators of 
blood took place along with the restoration of hystomorpho-
logical parameters of the liver. And only Selank contributed 
to an increase in the activity of regenerative processes.
The research proved that administering Selank and Se-
max to patients with pulmonary tuberculosis who already 
receive a massive antibacterial therapy would make it 
possible to decrease the number and intensity of hepato-
toxical reactions, to optimize the duration and scheme of 
polychemotherapy, and also to prevent the development 
of polyresistance of tuberculosis mycobacteria.
Conclusion
Selank and Semax have a pronounced hepatoprotective 
activity, superior to that of Essentiale and Mexidol. In 
view of their hepatoprotective activity, the drugs are rated 
as follows: Selank>Semax>Essentiale>Mexidol.
While administering Selank and Semax, a certain pa-
rallelism was observed between the restoration of bio-
chemical parameters of blood and histomorphological 
parameters of the liver, but an increase in the activity of 
regenerative processes was characteristic only of Selank.
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